KBG syndrome is an autosomal dominant disorder caused by pathogenic variants within ANKRD11 or deletions of 16q24.3 which include ANKRD11. It is characterized by distinctive facial features, developmental delay, short stature, and skeletal anomalies. We report 12 unrelated patients where a clinical diagnosis of KBG was suspected and confirmed by targeted analyses. Nine patients showed a point mutation in ANKRD11 (none of which were previously reported) and 3 carried a 16q24.3 deletion. All patients presented with typical facial features and macrodontia. Skeletal abnormalities were constant, and the majority of patients showed joint stiffness. Three patients required growth hormone treatment with a significant increase of height velocity. Brain malformations were identified in 8 patients. All patients showed behavioral abnormalities and most had developmental delay. Two patients had hematological abnormalities. We emphasize that genetic analysis of ANKRD11 can easily reach a detection rate higher than 50% thanks to clinical phenotyping, although it is known that a subset of ANKRD11-mutated patients show very mild features and will be more easily identified through the implementation of gene panels or exome sequencing. Joint stiffness was reported previously in few patients, but it seems to be a common feature and can be helpful for the diagnosis. Hematological abnormalities could be present and warrant a specific follow-up.

Keywords:
ANKRD11, 16q24.3 deletion, Joint stiffness, KBG syndrome, Macrodontia
1.
Ansari M, Poke G, Ferry Q, Williamson K, Aldridge R, et al: Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism. J Med Genet 51:659-668 (2014).
2.
Barber JCK, Maloney VK, Kirchhoff M, Thomas NS, Boyle TA, Castle B: Transmitted duplication of 12q21.32-12q22 includes 48 genes and has no apparent phenotypic consequences. Am J Med Genet A 143A:615-618 (2007).
3.
Cacciari E, Milani S, Balsamo A, Spada E, Bona G, et al: Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 29:581-593 (2006).
4.
Crippa M, Rusconi D, Castronovo C, Bestetti I, Russo S, et al: Familial intragenic duplication of ANKRD11 underlying three patients of KBG syndrome. Mol Cytogenet 8:20 (2015).
5.
Gallagher D, Voronova A, Zander MA, Cancino GI, Bramall A, et al: Ankrd11 is a chromatin regulator involved in autism that is essential for neural development. Dev Cell 32:31-42 (2015).
6.
Goldenberg A, Riccardi F, Tessier A, Pfund R, Busa T, et al: Clinical and molecular findings in 39 patients with KBG syndrome caused by deletion or mutation of ANKRD11. Am J Med Genet A 170:2847-2859 (2016).
7.
Herrmann J, Pallister PD, Tiddy W, Opitz JM: The KBG syndrome-a syndrome of short stature, characteristic facies, mental retardation, macrodontia and skeletal anomalies. Birth Defects Orig Art Ser 11:7-18 (1975).
8.
Isrie M, Hendriks Y, Glielissen N, Sistermans EA, Willemsen MH, et al: Haploinsufficiency of ANKRD11 causes mild cognitive impairment, short stature and minor dismorphisms. Eur J Hum Genet 20:131-133 (2012).
9.
Lim SP, Wong NC, Suetani RJ, Ho K, Ng JL, et al: Specific-site methylation of tumour suppressor ANKRD11 in breast cancer. Eur J Cancer 48:3300-3309 (2012).
10.
Lo-Castro A, Brancati F, Digilio MC, Garaci FG, Bollero P, et al: Neurobehavioral phenotype observed in KBG sydrome caused by ANKRD11 mutations. Am J Med Genet B Neuropsychiatr Genet 162B:17-23 (2013).
11.
Low K, Ashraf T, Canham N, Clayton-Smith J, Deshpande C, et al: Clinical and genetic aspects of KBG syndrome. Am J Med Genet A 170:2835-2846 (2016).
12.
Morel Swols D, Foster J 2nd, Tekin M: KBG syndrome. Orphanet J Rare Dis 12:183 (2017).
13.
Mucciolo M, Magini P, Marozza A, Mongelli P, Mencarelli MA, et al: 9q31.1q31.3 deletion in two patients with similar clinical features: a newly recognized microdeletion syndrome? Am J Med Genet A 164A:685-690 (2014).
14.
Murray N, Burgess B, Hay R, Colley A, Rajagopalan S, et al: KBG syndrome: an Australian experience. Am J Med Genet A 173A:1866-1877 (2017).
15.
Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, et al: Identification of ANKRD11 as a p53 coactivator. J Cell Sci 121:3541-3552 (2008).
16.
Novara F, Rinaldi B, Sisodiya SM, Coppola A, Giglio S, et al: Haploinsufficiency for ANKRD11-flanking genes makes the difference between KBG and 16q24.3 microdeletion syndromes: 12 new cases. Eur J Hum Genet 25:694-701 (2017).
17.
Ockeloen CW, Willemsen MH, de Munnik S, van Bon BW, de Leeuw N, et al: Further delineation of the KBG syndrome phenotype caused by ANKRD11 aberration. Eur J Hum Genet 23:1176-1185 (2015).
18.
Parenti I, Gervasini C, Pozojevic J, Graul-Neumann L, Azzollini J, et al: Broadening of cohesinopathies: exome sequencing identifies mutations in ANKRD11 in two patients with Cornelia de Lange-overlapping phenotype. Clin Genet 89:74-81 (2016).
19.
Posey JE, Harel T, Liu P, Rosenfeld JA, James RA, et al: Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med 376:21-31 (2017).
20.
Reynaert N, Ockeloen CW, Sävendahl L, Beckers D, Devriendt K, et al: Short stature in KBG syndrome: first responses to growth hormone treatment. Horm Res Paediatr 83:361-364 (2015).
21.
Sacharow S, Li D, Fan YS Tekin M: Familial 16q24.3 microdeletion involving ANKRD11 causes a KBG-like syndrome. Am J Med Genet A 158A:547-552 (2012).
22.
Schneider M, Debbané M, Bassett AS, Chow EW, Fung WL, et al: Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry 171:627-639 (2014).
23.
Sirmaci A, Spiliopoulos M, Brancati F, Powell E, Duman D, et al: Mutations in ANKRD11 cause KBG syndrome, characterized by intellectual disability, skeletal malformations, and macrodontia. Am J Hum Genet 89:289-294 (2011).
24.
Skjei KL, Martin MM, Slavotinek AM: KBG syndrome: report of twins, neurological characteristics, and delineation of diagnostic criteria. Am J Med Genet A 143A:292-300 (2007).
25.
Spengler S, Oehl-Jaschkowitz B, Begemann M, Hennes P, Zerres K, Eggermann T: Haploinsufficiency of ANKRD11 (16q24.3) is not obligatorily associated with cognitive impairment but shows a clinical overlap with Silver-Russell syndrome. Mol Syndromol 4:246-249 (2013).
26.
Tekin M, Kavaz A, Berberoğlu M, Fitoz S, Ekim M, et al: The KBG syndrome: confirmation of autosomal dominant inheritance and further delineation of the phenotype. Am J Med Genet A 130A:284-287 (2004).
27.
Tunovic S, Barkovich J, Sherr EH, Slavotinek AM: De novo ANKRD11 and KDM1A gene mutations in a male with features of KBG syndrome and Kabuki syndrome. Am J Med Genet A 164A:1744-1749 (2014).
28.
Walz K, Cohen D, Neilsen PM, Foster J 2nd, Brancati F, et al: Characterization of ANKRD11 mutations in humans and mice related to KBG syndrome. Hum Genet 134:181-190 (2015).
29.
Watrin E, Kaiser FJ, Wendt KS: Gene regulation and chromatin organization: relevance of cohesin mutations to human disease. Curr Opin Genet Dev 37:59-66 (2016).
30.
Willemsen MH, Fernandez BA, Bacino CA, Gerkes E, de Brouwer AP, et al: Identification of ANKRD11 and ZNF778 as candidate genes for autism and variable cognitive impairment in the novel 16q24.3 microdeletion syndrome. Eur J Hum Genet 18:429-435 (2010).
31.
Xu M, Zhou H, Yong J, Cong P, Li C, et al: A Chinese patient with KBG syndrome and a 9q31.2-33.1 microdeletion. Eur J Med Genet 56:245-250 (2013).
32.
Zhang A, Yeung PL, Li CW, Tsai SC, Dinh GK, et al: Identification of a novel family of ankirin repeats containing cofactors for p160 nuclear receptors coactivators. J Biol Chem 279:33799-33805 (2004).
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.